{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:48:29Z","timestamp":1783579709648,"version":"3.55.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,10,26]]},"DOI":"10.1001\/jama.2021.16496","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T16:12:33Z","timestamp":1633623153000},"page":"1606","source":"Crossref","is-referenced-by-count":127,"title":["Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barr\u00e9 Syndrome, February-July 2021"],"prefix":"10.1001","volume":"326","author":[{"given":"Emily Jane","family":"Woo","sequence":"first","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamma","family":"Mba-Jonas","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rositsa B.","family":"Dimova","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghna","family":"Alimchandani","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Zinderman","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Nair","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"joi210106r2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.15585\/mmwr.mm7009e4","article-title":"The advisory committee on immunization practices\u2019 interim recommendation for use of Janssen COVID-19 vaccine\u2014United States, February 2021.","volume":"70","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"joi210106r5","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)\u2014United States, 1991-2001.","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"issue":"36","key":"joi210106r6","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"pt 1","key":"joi210106r8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria.","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"issue":"24","key":"joi210106r10","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome.","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"joi210106r11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps.","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"joi210106r12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis.","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"2","key":"joi210106r14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977.","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"joi210106r7"},{"key":"joi210106r13","doi-asserted-by":"crossref","DOI":"10.1002\/0471445428","volume-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"2003","edition":"3rd ed"},{"key":"joi210106r1","unstructured":"US Food and Drug Administration. Janssen COVID-19 Vaccine. Accessed September 25, 2021. https:\/\/www.fda.gov\/media\/146303\/download"},{"key":"joi210106r3","unstructured":"US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency Use Authorization (EUA) of Janssen COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19). Published February 27, 2021. Revised August 27, 2021. Accessed September 25, 2021. https:\/\/www.fda.gov\/media\/146304\/download"},{"key":"joi210106r4","unstructured":"Vaccines and Related Biological Products Advisory Committee Meeting: FDA briefing document. Janssen Ad26.COV2.S Vaccine for the prevention of COVID-19; February 26, 2021. Accessed September 25, 2021. https:\/\/www.fda.gov\/media\/146217\/download"},{"key":"joi210106r9","unstructured":"COVID data tracker: COVID-19 vaccinations in the United States. Centers for Disease Control and Prevention. Posted September 30, 2021. Accessed September 25, 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations"},{"key":"joi210106r15","unstructured":"European Medicines Agency Science Medicines Health. COVID-19 vaccine safety update: vaxzevria AstraZeneca AB. Published July 14, 2021. Accessed August 19, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf"},{"key":"joi210106r16","unstructured":"European Medicines Agency Science Medicines Health. Vaxzevria product information. Accessed August 19, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf"},{"key":"joi210106r17","unstructured":"CBER biologics effectiveness and safety (BEST) system. US Food and Drug Administration. Updated December 4, 2020. Accessed August 19, 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-biologics-effectiveness-and-safety-best-system"},{"key":"joi210106r18","unstructured":"Medicare program: general information. Centers for Medicare & Medicaid Services. Updated January 14, 2021. Accessed August 19, 2021. https:\/\/www.cms.gov\/medicare\/medicare-general-information\/medicaregeninfo"},{"key":"joi210106r19","unstructured":"Vaccine safety monitoring. Centers for Disease Control and Prevention. Accessed August 19, 2021. https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2785009\/jama_woo_2021_oi_210106_1635192380.82276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T16:22:00Z","timestamp":1635265320000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2785009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":19,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,10,26]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.16496","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,26]]}}}